STOCK TITAN
  1. Home
  2. News
  3. HAE

Haemonetics to Present at Citi's 2024 Unplugged Medtech and Life Sciences Access Day

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Haemonetics Corporation's President and CEO, Chris Simon, will participate in a fireside chat with investors at Citi's 2024 Unplugged Medtech and Life Sciences Access Day. The webcast will be available for public access, with a replay option for 90 days.
Positive
  • None.
Negative
  • None.

BOSTON, Feb. 21, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at Citi's 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024 at 8:45 a.m. ET.

The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://kvgo.com/unplugged-medtech-life-sciences-access-day/haemonetics-corp-feb-2024. A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website.

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:


Olga Guyette, Sr. Director-Investor Relations & Treasury

David Trenk, Manager-Investor Relations

(781) 356-9763

(203) 733-4987

olga.guyette@haemonetics.com

david.trenk@haemonetics.com



Media Contact:


Josh Gitelson, Director-Global Communications


(781) 356-9776


josh.gitelson@haemonetics.com 


Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-to-present-at-citis-2024-unplugged-medtech-and-life-sciences-access-day-302068093.html

SOURCE Haemonetics Corporation

Chris Simon will participate in the fireside chat on Thursday, February 29, 2024, at 8:45 a.m. ET.

The public can access the live webcast of the fireside chat at Haemonetics' Investor Relations website or at the provided link: https://kvgo.com/unplugged-medtech-life-sciences-access-day/haemonetics-corp-feb-2024.

The replay of the recorded webcast will be accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website.
Stock HAE logo
Haemonetics Corp.

NYSE:HAE

HAE Rankings

#1247 Ranked by Market Cap
#2026 Ranked by Stock Gains
N/A Ranked by Dividends

HAE Latest News

Apr 10, 2024
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024
Apr 4, 2024
Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge
Apr 1, 2024
Haemonetics Corporation Completes Acquisition of Attune Medical
Mar 5, 2024
Haemonetics Announces Definitive Agreement to Acquire Attune Medical
Feb 21, 2024
Haemonetics to Present at Raymond James 45th Annual Institutional Investors Conference

HAE Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
US
Boston

About HAE

haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right